<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117658</url>
  </required_header>
  <id_info>
    <org_study_id>HA122-CSP-004</org_study_id>
    <nct_id>NCT05117658</nct_id>
  </id_info>
  <brief_title>Study of HA121-28 in Patients With Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Single-Arm, Multi-Centre, Open-Label Phase II Study of HA121-28 in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label, single-arm phase II study to evaluate efficacy and&#xD;
      safety of HA121-28 tablets in patients with rearranged during transfection (RET)&#xD;
      fusion-positive advanced non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The percentage of patients who achieve a complete response (CR) or partial response (PR) evaluated by Independent Review Committee (IRC) according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The percentage of patients who achieve a CR or PR evaluated by investigator according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Time from date of the first dose to date of recorded disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Evaluated by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 24 months</time_frame>
    <description>Time from date of the first dose to date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>The percentage of patients who achieve a CR, PR or stable disease (SD) evaluated by IRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Evaluated by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Time from first documented response (CR or PR, whichever occurs first, evaluated by IRC) to date of disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Evaluated by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-related adverse events (AEs) and serious adverse events (SAEs).</measure>
    <time_frame>Up to 28 days after the last administration of HA121-28</time_frame>
    <description>The AEs and SAEs will be assessed according to the National Cancer Institute (NCI) CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>HA121-28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive HA121-28 tablets at 600 mg once daily (QD) for 21 days on a 28-day treatment cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HA121-28 tablet</intervention_name>
    <description>HA121-28 tablet, 600 mg, po, QD×21 days, every 4 weeks (28 days)</description>
    <arm_group_label>HA121-28</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Voluntarily participate in this study and sign the informed consent form;&#xD;
&#xD;
          2. Aged 18 ~ 75 years old (inclusive), male or female;&#xD;
&#xD;
          3. Patients with histologically or cytologically confirmed unresectable locally advanced&#xD;
             or metastatic non-small cell lung cancer;&#xD;
&#xD;
          4. RET gene fusion, as demonstrated by &quot;Next-generation&quot; sequencing(NGS) method in&#xD;
             central laboratory with College of American Pathologists(CAP) or Clinical Laboratory&#xD;
             Improvement Amendments(CLIA) certification;&#xD;
&#xD;
          5. Progressive disease after at least one line of standard therapy (including patients&#xD;
             with disease progression during or within 6 months of the end of adjuvant therapy);&#xD;
&#xD;
          6. At least one measurable lesion according to RECIST 1.1 (for lesions previously treated&#xD;
             with radiation, the lesion can be included as a measurable lesion only if there is&#xD;
             clear disease progression after radiotherapy);&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) score 0-1;&#xD;
&#xD;
          8. Adequate organ function, laboratory tests meeting the following criteria:&#xD;
&#xD;
               -  Neutrophil count (ANC) ≥ 1.5 × 10^9/L (no G-CSF for WBC-elevating therapy within&#xD;
                  2 weeks prior to the laboratory test);&#xD;
&#xD;
               -  Platelet count (PLT) ≥ 75 × 10^9/L (no platelet transfusion or other drugs to&#xD;
                  promote platelet production within 2 weeks prior to the laboratory test);&#xD;
&#xD;
               -  Hemoglobin (Hb) ≥ 90 g/L; (not receiving red blood cell transfusion or&#xD;
                  erythropoiesis-stimulating drugs within 2 weeks prior to the laboratory test);&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × upper&#xD;
                  limit of normal (ULN) (≤ 5.0 × ULN for patients with liver metastases);&#xD;
&#xD;
               -  Serum total bilirubin (TBIL) ≤ 1.5 × ULN;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 × ULN;&#xD;
&#xD;
               -  Albumin ≥ 30 g/L;&#xD;
&#xD;
          9. Male and female patients of childbearing age agree to take effective contraceptive&#xD;
             measures during treatment and within 6 months after the completion of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had a documented oncogenic driver gene alteration other than RET in NSCLC, ie,&#xD;
             activating EGFR, BRAF, or KRAS mutation, MET exon 14 skipping mutation or high-level&#xD;
             amplification, and ALK, ROS1, or NTRK1/2/3 gene fusions;&#xD;
&#xD;
          2. Prior treatment with selective RET inhibitors (including investigational selective RET&#xD;
             inhibitors, such as LOXO-292, BLU-667, RXDX-105, etc.);&#xD;
&#xD;
          3. Patients who previously received any anti-tumor therapy (including but not limited to&#xD;
             chemotherapy, radiotherapy and targeted therapy, etc.) within 4 weeks before the first&#xD;
             use of the study drug; traditional Chinese medicine or Chinese patent medicine with&#xD;
             anti-tumor indications within 2 weeks; local palliative radiotherapy for the relief of&#xD;
             bone metastasis pain within 2 weeks;&#xD;
&#xD;
          4. Abnormal coagulation function (INR &gt; 1.5 or APTT &gt; 1.5 × ULN); patients with bleeding&#xD;
             tendency (such as active peptic ulcer) or receiving thrombolytic or anticoagulant&#xD;
             therapy;&#xD;
&#xD;
          5. Urine routine showed urine protein ≥ + + and 24 h urine protein &gt; 1.0 g;&#xD;
&#xD;
          6. Patients who have undergone major surgical procedures within 4 weeks before the first&#xD;
             dose or are expected to undergo major surgery during the study;&#xD;
&#xD;
          7. Patients with central nervous system (CNS) metastases who present with progressive&#xD;
             neurological symptoms or require an increase in corticosteroid dose to control their&#xD;
             CNS disease. If a patient requires treatment with corticosteroids for CNS disease, the&#xD;
             dose must be stable for two weeks prior to the first dose;&#xD;
&#xD;
          8. Presence of poorly controlled pericardial, pleural, or peritoneal effusion;&#xD;
&#xD;
          9. Interstitial pneumonia requiring steroid therapy, drug-induced pneumonitis, radiation&#xD;
             pneumonitis (except for stable radiation pneumonitis);&#xD;
&#xD;
         10. Significant cardiovascular disease, such as heart failure greater than New York Heart&#xD;
             Association (NYHA) Class 2, unstable angina, serious arrhythmia, myocardial infarction&#xD;
             or stroke within 6 months prior to the first dose, poorly controlled hypertension&#xD;
             (defined as systolic blood pressure &gt; 150 mmHg or diastolic blood pressure &gt; 100 mmHg&#xD;
             on multiple measurements while on medication);&#xD;
&#xD;
         11. Patients who met any of the following criteria will be excluded:&#xD;
&#xD;
               -  QT interval (QTcF) value ≥ 470 ms for females and ≥ 450 ms for males; or&#xD;
                  congenital long QT syndrome, taking drugs known to prolong QT interval, family&#xD;
                  history of long QT syndrome;&#xD;
&#xD;
               -  Resting ECG showed any clinically significant abnormalities in rhythm,&#xD;
                  conduction, or morphology that required clinical intervention;&#xD;
&#xD;
               -  Cardiac ejection fraction less than 50%;&#xD;
&#xD;
         12. Patients with active hepatitis B virus or hepatitis C virus infection:&#xD;
&#xD;
               -  HBsAg positive with HBV DNA higher than the upper limit of normal range of the&#xD;
                  study site;&#xD;
&#xD;
               -  HCV antibody positive with HCV RNA higher than upper limit of normal range of the&#xD;
                  site;&#xD;
&#xD;
         13. Human immunodeficiency virus infected (HIV positive);&#xD;
&#xD;
         14. Inability or severe dysphagia;&#xD;
&#xD;
         15. Patients who have suffered from or are complicated with any other malignant tumor&#xD;
             within 5 years (except radically resected skin basal cell carcinoma, skin squamous&#xD;
             cell carcinoma, superficial bladder cancer, local prostate cancer, in situ cervical&#xD;
             cancer or other carcinoma in situ);&#xD;
&#xD;
         16. Presence of any severe and/or uncontrolled disease that may affect the drug evaluation&#xD;
             in the judgment of the investigator, including but not limited to: life-threatening&#xD;
             autoimmune system diseases; drug abuse; severe nervous system diseases (such as&#xD;
             epilepsy, dementia, etc.); history of severe mental disorders; severe infection, etc.;&#xD;
&#xD;
         17. Pregnant or lactating women;&#xD;
&#xD;
         18. Other conditions that, in the opinion of the investigator, make participation in the&#xD;
             study unsuitable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruihua Xu, Ph.D</last_name>
    <phone>86-20-87343468</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruihua Xu, Ph.D</last_name>
      <phone>86-20-87343468</phone>
      <email>xurh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

